Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease
T Molnár, K Farkas, É Pallagi, R Gyulai, R Kui, Z Szepes, M Szűcs, F Nagy, T Wittmann · Zeitschrift für Gastroenterologie · 2012 · Heft 05
Bibliografische Angaben
Zusammenfassung
Introduction: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD). Nevertheless, up to 40% of patients lose response to infliximab and 10% develops severe side effects or allergic reaction. The aim of this study was to assess the clinical value of measuring infliximab trough levels (TL) and antibodies to infliximab (ATI) concentrations in IBD patients who lost response or developed adverse reaction to infliximab therapy. Patients and methods: The records of 43 IBD patients (22 CD, 21 UC; mean age at the diagnosis 29.6 years, mean age at the start of biological therapy 36.7 ye…
